The importance of truncal somatic mutations in MRD testing
Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.
The importance of truncal somatic mutations in MRD testing
Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.
Tumor-naive versus tumor-informed approaches to MRD testing
One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed or whether they are tumor-naive.
Haystack MRD™: Foundational clinical efficacy
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
DNA input and number of mutations tracked: a balancing act
Haystack MRD™ strikes the right balance of DNA molecules interrogated and number of mutations tracked for optimizing test efficiency and sustainability
